Physician profile
Edwin A Diaz
NPI 1275508939
$125,456.40
in general payments reported to CMS, 2019-2025
17 companies · $184 in 2025
The $184 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $38K · 2020: $27K · 2021: $23K · 2022: $24K · 2023: $207 · 2024: $14K · 2025: $184.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $14K · Food and Beverage: $539.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $13,500.00 |
| Food and Beverage | $539.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Cryo Specialty Medical, LLC | $124,500.00 | 2019-2024 | |
| Procept Biorobotics Corporation | $235.80 | 2023-2024 | Aquabeam Robotic System, Aquabeam System |
| Teleflex LLC | $168.96 | 2024-2025 | Barrigel, Urolift |
| Allergan, INC. | $112.14 | 2019-2021 | |
| Axonics, INC. | $71.99 | 2020-2024 | Axonics |
| Amgen INC. | $65.74 | 2021-2022 | |
| Rochester Medical Corporation | $62.44 | 2021-2022 | |
| Blue Earth Diagnostics | $46.17 | 2019-2022 | |
| Dendreon Pharmaceuticals LLC | $30.29 | 2022 | |
| Medtronic USA, INC. | $29.33 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $29.29 | 2025 | |
| Verity Pharmaceuticals INC. | $25.00 | 2022 | |
| Neotract INC. | $20.75 | 2019 | |
| Olympus America INC. | $16.67 | 2025 | Itind System |
| Pfizer INC. | $14.42 | 2023 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $13.79 | 2023 | Gemtesa |
| Coloplast Corp | $13.62 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$394,464.73 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edwin Diaz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.